Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses

J. P. Tolins, R. M J Palmer, S. Moncada, Leopoldo Raij

Research output: Contribution to journalArticle

277 Citations (Scopus)

Abstract

An endothelium-derived relaxing factor (EDRF) has recently been identified as nitric oxide (NO), originating from endothelial cell metabolism of L-arginine. In vitro studies suggest that EDRF/NO stimulates soluble guanylate cyclase and increases guanosine 3',5'-cyclic monophosphate (cGMP) levels in vascular smooth muscle cells, resulting in the vasorelaxant effects of endothelium-dependent vasodilators such as acetylcholine (ACh). The importance of EDRF/NO in normal physiology or disease states remains uncertain. We therefore investigated the relationship between ACh-induced hemodynamic responses, synthesis of EDRF/NO, and changes in the rate of urinary cGMP excretion in the anesthetized rat in vivo. Intravenous infusion of ACh resulted in hypotension, maintenance of glomerular filtration rate, and renal vasodilatation. ACh induced a dose-dependent increase in urinary cGMP excretion, an effect that was not observed with equihypotensive doses of the endothelium-independent vasodilator, prostacyclin. Rates of cGMP excretion were significantly correlated with the fall in systemic blood pressure induced by ACh. Treatment with N(G)-monomethyl-L-arginine (L-NMMA), an inhibitor of enzymatic synthesis of nitric oxide from L-arginine, prevented the ACh-induced increase in urinary cGMP excretion as well as the systemic and renal hemodynamic effects of ACH. Plasma levels of atrial natriuretic peptide were unchanged by ACh infusion. Intravenous infusion of L-NMMA was associated with increased blood pressure and decreased basal rates of urinary cGMP excretion. This hypertensive effect was reversed by administration of L-arginine. We conclude that 1) EDRF/NO mediates the hemodynamic effects of ACh in vivo; 2) urinary excretion of cGMP is a biological marker of EDRF/NO activity; and 3) basal production of EDRF/NO may play a role in regulation of systemic blood pressure and renal hemodynamics.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume258
Issue number3 27-3
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Endothelium-Dependent Relaxing Factors
Acetylcholine
Nitric Oxide
Hemodynamics
Kidney
Arginine
omega-N-Methylarginine
Blood Pressure
Vasodilator Agents
Intravenous Infusions
Cyclic GMP
Atrial Natriuretic Factor
Epoprostenol
Glomerular Filtration Rate
Vascular Smooth Muscle
Vasodilation
Hypotension
Smooth Muscle Myocytes
Endothelium
Endothelial Cells

Keywords

  • guanosine 3',5'-cyclic monophosphate
  • L-arginine
  • L-N(G)-monomethylarginine
  • nitric oxide
  • prostacyclin
  • vascular endothelium

ASJC Scopus subject areas

  • Physiology

Cite this

Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. / Tolins, J. P.; Palmer, R. M J; Moncada, S.; Raij, Leopoldo.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 258, No. 3 27-3, 01.01.1990.

Research output: Contribution to journalArticle

@article{ca6594ee62e748df9880001384b3417c,
title = "Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses",
abstract = "An endothelium-derived relaxing factor (EDRF) has recently been identified as nitric oxide (NO), originating from endothelial cell metabolism of L-arginine. In vitro studies suggest that EDRF/NO stimulates soluble guanylate cyclase and increases guanosine 3',5'-cyclic monophosphate (cGMP) levels in vascular smooth muscle cells, resulting in the vasorelaxant effects of endothelium-dependent vasodilators such as acetylcholine (ACh). The importance of EDRF/NO in normal physiology or disease states remains uncertain. We therefore investigated the relationship between ACh-induced hemodynamic responses, synthesis of EDRF/NO, and changes in the rate of urinary cGMP excretion in the anesthetized rat in vivo. Intravenous infusion of ACh resulted in hypotension, maintenance of glomerular filtration rate, and renal vasodilatation. ACh induced a dose-dependent increase in urinary cGMP excretion, an effect that was not observed with equihypotensive doses of the endothelium-independent vasodilator, prostacyclin. Rates of cGMP excretion were significantly correlated with the fall in systemic blood pressure induced by ACh. Treatment with N(G)-monomethyl-L-arginine (L-NMMA), an inhibitor of enzymatic synthesis of nitric oxide from L-arginine, prevented the ACh-induced increase in urinary cGMP excretion as well as the systemic and renal hemodynamic effects of ACH. Plasma levels of atrial natriuretic peptide were unchanged by ACh infusion. Intravenous infusion of L-NMMA was associated with increased blood pressure and decreased basal rates of urinary cGMP excretion. This hypertensive effect was reversed by administration of L-arginine. We conclude that 1) EDRF/NO mediates the hemodynamic effects of ACh in vivo; 2) urinary excretion of cGMP is a biological marker of EDRF/NO activity; and 3) basal production of EDRF/NO may play a role in regulation of systemic blood pressure and renal hemodynamics.",
keywords = "guanosine 3',5'-cyclic monophosphate, L-arginine, L-N(G)-monomethylarginine, nitric oxide, prostacyclin, vascular endothelium",
author = "Tolins, {J. P.} and Palmer, {R. M J} and S. Moncada and Leopoldo Raij",
year = "1990",
month = "1",
day = "1",
language = "English",
volume = "258",
journal = "American Journal of Physiology - Cell Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "3 27-3",

}

TY - JOUR

T1 - Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses

AU - Tolins, J. P.

AU - Palmer, R. M J

AU - Moncada, S.

AU - Raij, Leopoldo

PY - 1990/1/1

Y1 - 1990/1/1

N2 - An endothelium-derived relaxing factor (EDRF) has recently been identified as nitric oxide (NO), originating from endothelial cell metabolism of L-arginine. In vitro studies suggest that EDRF/NO stimulates soluble guanylate cyclase and increases guanosine 3',5'-cyclic monophosphate (cGMP) levels in vascular smooth muscle cells, resulting in the vasorelaxant effects of endothelium-dependent vasodilators such as acetylcholine (ACh). The importance of EDRF/NO in normal physiology or disease states remains uncertain. We therefore investigated the relationship between ACh-induced hemodynamic responses, synthesis of EDRF/NO, and changes in the rate of urinary cGMP excretion in the anesthetized rat in vivo. Intravenous infusion of ACh resulted in hypotension, maintenance of glomerular filtration rate, and renal vasodilatation. ACh induced a dose-dependent increase in urinary cGMP excretion, an effect that was not observed with equihypotensive doses of the endothelium-independent vasodilator, prostacyclin. Rates of cGMP excretion were significantly correlated with the fall in systemic blood pressure induced by ACh. Treatment with N(G)-monomethyl-L-arginine (L-NMMA), an inhibitor of enzymatic synthesis of nitric oxide from L-arginine, prevented the ACh-induced increase in urinary cGMP excretion as well as the systemic and renal hemodynamic effects of ACH. Plasma levels of atrial natriuretic peptide were unchanged by ACh infusion. Intravenous infusion of L-NMMA was associated with increased blood pressure and decreased basal rates of urinary cGMP excretion. This hypertensive effect was reversed by administration of L-arginine. We conclude that 1) EDRF/NO mediates the hemodynamic effects of ACh in vivo; 2) urinary excretion of cGMP is a biological marker of EDRF/NO activity; and 3) basal production of EDRF/NO may play a role in regulation of systemic blood pressure and renal hemodynamics.

AB - An endothelium-derived relaxing factor (EDRF) has recently been identified as nitric oxide (NO), originating from endothelial cell metabolism of L-arginine. In vitro studies suggest that EDRF/NO stimulates soluble guanylate cyclase and increases guanosine 3',5'-cyclic monophosphate (cGMP) levels in vascular smooth muscle cells, resulting in the vasorelaxant effects of endothelium-dependent vasodilators such as acetylcholine (ACh). The importance of EDRF/NO in normal physiology or disease states remains uncertain. We therefore investigated the relationship between ACh-induced hemodynamic responses, synthesis of EDRF/NO, and changes in the rate of urinary cGMP excretion in the anesthetized rat in vivo. Intravenous infusion of ACh resulted in hypotension, maintenance of glomerular filtration rate, and renal vasodilatation. ACh induced a dose-dependent increase in urinary cGMP excretion, an effect that was not observed with equihypotensive doses of the endothelium-independent vasodilator, prostacyclin. Rates of cGMP excretion were significantly correlated with the fall in systemic blood pressure induced by ACh. Treatment with N(G)-monomethyl-L-arginine (L-NMMA), an inhibitor of enzymatic synthesis of nitric oxide from L-arginine, prevented the ACh-induced increase in urinary cGMP excretion as well as the systemic and renal hemodynamic effects of ACH. Plasma levels of atrial natriuretic peptide were unchanged by ACh infusion. Intravenous infusion of L-NMMA was associated with increased blood pressure and decreased basal rates of urinary cGMP excretion. This hypertensive effect was reversed by administration of L-arginine. We conclude that 1) EDRF/NO mediates the hemodynamic effects of ACh in vivo; 2) urinary excretion of cGMP is a biological marker of EDRF/NO activity; and 3) basal production of EDRF/NO may play a role in regulation of systemic blood pressure and renal hemodynamics.

KW - guanosine 3',5'-cyclic monophosphate

KW - L-arginine

KW - L-N(G)-monomethylarginine

KW - nitric oxide

KW - prostacyclin

KW - vascular endothelium

UR - http://www.scopus.com/inward/record.url?scp=0025269712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025269712&partnerID=8YFLogxK

M3 - Article

C2 - 2156453

AN - SCOPUS:0025269712

VL - 258

JO - American Journal of Physiology - Cell Physiology

JF - American Journal of Physiology - Cell Physiology

SN - 0363-6143

IS - 3 27-3

ER -